Skip to main content

Drug Interaction Report

2 potential interactions and/or warnings found for the following 2 drugs:

Add another drug
Filter by interaction and/or warning

Interactions between your drugs

Moderate

selexipag maribavir

Applies to: selexipag, maribavir

MONITOR: Coadministration with maribavir may increase the plasma concentrations of drugs that are substrates of the breast cancer resistance protein (BCRP) transporter. The proposed mechanism is decreased clearance due to maribavir-mediated inhibition of the BCRP transport protein. There are no clinical data regarding the use of maribavir with BCRP substrates.

MANAGEMENT: Caution is advised when maribavir is prescribed with drugs that are BCRP substrates, particularly those with a narrow therapeutic range. Clinical and laboratory monitoring as well as dosage adjustments may be appropriate for some drugs whenever maribavir is added to or withdrawn from therapy.

References (1)
  1. (2021) "Product Information. Livtencity (maribavir)." Takeda Pharmaceuticals America

Drug and food interactions

Minor

selexipag food

Applies to: selexipag

Food prolongs the gastrointestinal absorption of selexipag. When taken with food, the time to peak concentration (Tmax) was delayed and peak plasma concentration (Cmax) was approximately 30% lower. Selexipag systemic exposure (AUC) and that of its active metabolite did not significantly change, however. Selexipag may be taken with or without food. Tolerability may be improved when taken with food.

References (1)
  1. (2016) "Product Information. Uptravi (selexipag)." Actelion Pharmaceuticals US Inc

Therapeutic duplication warnings

No duplication warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Learn more

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer